Interleukin-18 production and pulmonary function in COPD

Imaoka, Haruki; Hoshino, Tomoaki; Takei, Satoko; Kinoshita, Takashi; Okamoto, Masaki; Kawayama, Tomotaka; Kato, Seiya; Iwasaki, Hiroshi; Watanabe, Kei; Aizawa, Hisamichi

doi:10.1183/09031936.00019207

Cited by 122 publications

(109 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immunohistochemical assay and immunoreactivity score Immunohistochemical analysis was performed as reported previously [15][16][17]. Briefly, rat anti-human periostin mAbs (clone no.…”

Section: Pulmonary Function Testmentioning

confidence: 99%

Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias

et al. 2010

Self Cite

View full text Add to dashboard Cite

Idiopathic interstitial pneumonias (IIPs) are histopathologically classified into several types, including usual interstitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP) and cryptogenic organising pneumonia (COP). We investigated whether periostin, a matrix protein, could be used as a biomarker to assess histopathological types of IIPs.We performed immunohistochemical analyses in each histopathological type of IIP, examined serum levels of periostin in IIP patients and analysed the relationship between serum levels of periostin and the pulmonary functions in patients with idiopathic pulmonary fibrosis (IPF).Periostin was strongly expressed in lungs of UIP and fibrotic NSIP patients, whereas expression of periostin was weak in the lungs of cellular NSIP and COP patients, as well as in normal lungs. Serum levels of periostin in IPF were significantly higher than those of healthy subjects and COP patients. Furthermore, periostin levels in IPF patients were inversely correlated with their pulmonary functions.Thus, we have found that periostin is a novel component of fibrosis in IIP. Periostin may be a potential biomarker to distinguish IIP with fibrosis.

show abstract

“…Immunohistochemical assay and immunoreactivity score Immunohistochemical analysis was performed as reported previously [15][16][17]. Briefly, rat anti-human periostin mAbs (clone no.…”

Section: Pulmonary Function Testmentioning

confidence: 99%

Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias

et al. 2010

Self Cite

View full text Add to dashboard Cite

show abstract

“…IL-18 contributes to a number of inflammatory disorders, including rheumatoid arthritis (14), Crohn's disease, and sarcoidosis (15). Overproduction of IL-18 is associated with the pathogenesis of chronic obstructive pulmonary disease (COPD) (16). Mice deficient in IL-18 have impaired IFN-g production, and macrophages of these animals fail to promote Th1 responses in vitro (17).…”

mentioning

confidence: 99%

IL-8 Dictates Glycosaminoglycan Binding and Stability of IL-18 in Cystic Fibrosis

Reeves

Williamson

Byrne

et al. 2009

The Journal of Immunology

View full text Add to dashboard Cite

Dysregulation of airway inflammation contributes to lung disease in cystic fibrosis (CF). Inflammation is mediated by inflammatory cytokines, including IL-8, which illustrates an increase in biological half-life and proinflammatory activity when bound to glycosaminoglycans (GAGs). The aim of this project was to compare IL-8 and IL-18 for their relative stability, activity, and interaction with GAGs, including chondroitin sulfate, hyaluronic acid, and heparan sulfate, present in high quantities in the lungs of patients with CF. Bronchoalveolar lavage fluid was collected from patients with CF (n = 28), non-CF controls (n = 14), and patients with chronic obstructive pulmonary disease (n = 12). Increased levels of IL-8 and reduced concentrations of IL-18 were detected in bronchial samples obtained from CF individuals. The low level of IL-18 was not a defect in IL-18 production, as the pro- and mature forms of the molecule were expressed and produced by CF epithelial cells and monocytes. There was, however, a marked competition between IL-8 and IL-18 for binding to GAGs. A pronounced loss of IL-18 binding capacity occurred in the presence of IL-8, which displaced IL-18 from these anionic-matrices, rendering the cytokine susceptible to proteolytic degradation by neutrophil elastase. As a biological consequence of IL-18 degradation, reduced levels of IL-2 were secreted by Jurkat T lymphocytes. In conclusion, a novel mechanism has been identified highlighting the potential of IL-8 to determine the fate of other inflammatory molecules, such as IL-18, within the inflammatory milieu of the CF lung.

show abstract

“…Se ha reportado que los enfermos de EPOC presentan un mayor porcentaje de células Th1 y que secretan más IFN-γ que en fumadores control 73 . Además, en los pacientes con EPOC grave se ha observado una alta expresión de IL-18, citoquina que promueve el desarrollo de las células Th1 74 . En cuanto a las células Th17, las cuales están implicadas en procesos autoinmunes y en el reclutamiento de otras células inflamatorias a tejidos 75 , se encuentran incrementadas en sangre de enfermos de EPOC en comparación a fumadores control 76 .…”

Section: Los Linfocitos T Cd4unclassified

Efectores celulares de la respuesta inflamatoria en la enfermedad pulmonar obstructiva crónica

Montés

García‐Valero³

et al. 2015

Rev. méd. Chile

View full text Add to dashboard Cite

Approximately 3 million people in the world die every year as a consequence of COPD, which is associated with an abnormal inflammatory response of the lung to noxious particles and gases. This inflammatory pattern causes pathological changes leading to a narrowing of small airways and destruction of lungjordiog82@gmail.com L a enfermedad pulmonar obstructiva crónica (EPOC) es un proceso patológico de alta prevalencia, considerado en la actualidad la cuarta causa de muerte en el mundo y que, se estima, se convertirá en la tercera en el año 2030 1 . En los países de América Latina, 35 de cada 1.000 hospitalizaciones se deben a la EPOC, con un alto coste económico y con rangos de mortalidad intrahospitalaria que van de 6,7% a 29,5% 2 . En Chile, las enfermedades respiratorias constituyen la tercera causa de muerte y, entre ellas, la EPOC ocupa el segundo lugar, representando a 22% de los decesos 3 . Por su parte, el Proyecto Latinoamericano de Investigación en Obstrucción Pulmonar (PLATINO) ha reportado que la prevalencia de la EPOC en Santiago de Chile es de 6,3% en la población mayor de 40 años 4 . La EPOC se define como una enfermedad caracterizada por una limitación al flujo aéreo no completamente reversible, progresiva y que se asocia a una respuesta inflamatoria anormal de los pulmones a partículas nocivas o gases 5 . Esta enfermedad comprende tanto los síntomas clínicos de la bronquitis/bronquiolitis crónica como los de la patología derivada del enfisema pulmonar. La confirmación diagnóstica se obtiene al realizar pruebas espirométricas, las cuales permiten determinar la obstrucción del flujo aéreo y el grado de alteración de la función pulmonar a partir del volumen espirado forzado en el primer segundo (VEF 1 ), la capacidad vital forzada (CVF) y la relación de estos dos parámetros clínicos (VEF 1 /CVF) 5 . Se considera al humo del tabaco como el prin-

show abstract

Interleukin-18 production and pulmonary function in COPD

Cited by 122 publications

References 36 publications

Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias

Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias

IL-8 Dictates Glycosaminoglycan Binding and Stability of IL-18 in Cystic Fibrosis

Efectores celulares de la respuesta inflamatoria en la enfermedad pulmonar obstructiva crónica

Contact Info

Product

Resources

About